Isaac Manke
Partner @ Acorn Bioventures
New York, United States
Isaac Manke is a Series B investor at Acorn Bioventures in New York focused on Health Care and Therapeutics. Isaac Manke is the Partner at Acorn Bioventures. Attended Massachusetts Institute of Technology.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Isaac Manke invests in
Stages Isaac Manke invests in
Countries Isaac Manke invests in
Investment Focus
Industry
- Health Care 3 (38%)
- Therapeutics 3 (38%)
- Biotechnology 3 (38%)
- Medical 1 (13%)
- Life Science 1 (13%)
Stage
- Series B 2 (25%)
- Series C 2 (25%)
- Post-IPO Equity 2 (25%)
- Series A 1 (13%)
- Funding Round 1 (13%)
Country
- United States 3 (38%)
- Ireland 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
OnKure Therapeutics
|
OnKure is a biotechnology company that commercializes a new cancer therapy based on novel, less toxic kinase inhibitor drugs. The company is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that includes selective inhibitors of histone deacetylases. In pre-clinical models of both hematological and solidtumor cancers, their lead candidate, OKI-179, significantly and safely reduces the growth rate of tumors when dosed by itself or in combination with other targeted therapies.OnKure advances the HDAC3 selective inhibitor OKI-422 into pre-clinical toxicology studies. The company's drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized. | $65M / Post-IPO Equity / Oct 04, 2024 | |
Q32 Bio
|
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.Q32 Bio consists of ateam of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies. | $42M / Mar 25, 2024 | |
|
Q32 Bio
|
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.Q32 Bio consists of ateam of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies. | $42M / Post-IPO Equity / Mar 25, 2024 | |
|
OnKure Therapeutics
|
OnKure is a biotechnology company that commercializes a new cancer therapy based on novel, less toxic kinase inhibitor drugs. The company is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that includes selective inhibitors of histone deacetylases. In pre-clinical models of both hematological and solidtumor cancers, their lead candidate, OKI-179, significantly and safely reduces the growth rate of tumors when dosed by itself or in combination with other targeted therapies.OnKure advances the HDAC3 selective inhibitor OKI-422 into pre-clinical toxicology studies. The company's drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized. | $54M / Series C / May 23, 2023 | |
ONK Therapeutics
|
ONK Therapeutics is an innovative cell therapy company dedicated to developing the next generation of off-the-shelf, optimally engineered natural killer (NK) cell therapies targeting both hematological malignancies and solid tumors. | $21.5M / Series A / Jan 06, 2022 | |
|
OnKure Therapeutics
|
OnKure is a biotechnology company that commercializes a new cancer therapy based on novel, less toxic kinase inhibitor drugs. The company is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that includes selective inhibitors of histone deacetylases. In pre-clinical models of both hematological and solidtumor cancers, their lead candidate, OKI-179, significantly and safely reduces the growth rate of tumors when dosed by itself or in combination with other targeted therapies.OnKure advances the HDAC3 selective inhibitor OKI-422 into pre-clinical toxicology studies. The company's drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized. | $56.6M / Series B / Mar 04, 2021 | |
|
Q32 Bio
|
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.Q32 Bio consists of ateam of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies. | $60M / Series B / Oct 29, 2020 | |
True North Therapeutics
|
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North iscurrently focused on Complement-mediated rare diseases in the hematologic, kidney transplant, dermatology, and neurological space. True North was formed in 2013 as a spin-out of iPierian. | $40M / Series C / Dec 03, 2015 |
Co-Investors
Cormorant Asset Management
6 deals together
Abingworth
3 deals together
Atlas Venture
3 deals together
OrbiMed
3 deals together
OUP (Osage University Partners)
3 deals together
Perceptive Advisors
3 deals together
About Acorn Bioventures
Our invest in and partner with private and small capitalization biotech, specialty pharma and medical device companies.
Acorn Bioventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anders Hove
Partner & Founder
|
|||
|
Isaac Manke
Partner
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Isaac Manke invest in?
Isaac Manke invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series B and Series C stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Isaac Manke last invest?
The most recent investment recorded for Isaac Manke closed in Oct 2024. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
